Recent advances in pharmacotherapy of multiple sclerosis

A tétel rövid nézete
dc.contributor.advisorMegyeri, Atilla
dc.contributor.advisordeptÁltalános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet
dc.contributor.authorTurgeman, Shira
dc.contributor.departmentDE--Általános Orvostudományi Kar
dc.contributor.opponentSzentmiklósi, József
dc.contributor.opponentDrimba, László
dc.contributor.opponentdeptÁltalános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet
dc.contributor.opponentdeptÁltalános Orvostudományi Kar::Aneszteziológiai és Intenzív Terápiás Tanszék
dc.date.accessioned2024-03-21T11:45:58Z
dc.date.available2024-03-21T11:45:58Z
dc.date.created2024-03-21
dc.description.abstractIn recent decades, the treatment approach for multiple sclerosis (MS) has experienced a significant change. There is now a growing collection of Disease-Modifying Therapies (DMTs) that have proven to be highly effective in treating relapsing-remitting forms of disease. These therapies have been shown to significantly decrease the occurrence and intensity of symptoms. Yet, the complex and intricate path towards finding a conclusive remedy is hindered by significant challenges. The progressive form of multiple sclerosis (MS), which combines neurodegeneration and chronic inflammation, poses a complex and challenging problem. Despite the availability of restricted treatment options, they only provide partial relief. Although existing disease-modifying therapies (DMTs) effectively reduce the occurrence of relapses and decrease inflammation that can be detected using MRI, their strong immunosuppressive mechanisms have a potential drawback. This means that patients are at an increased risk of experiencing negative side effects. The need to create advanced treatment plans that achieve a balance between effective disease management and patient welfare is highlighted by this difficult compromise. Moreover, the diverse nature of multiple sclerosis (MS), shaped by complex interactions between environmental, genetic, and immunological factors, necessitates a transition towards targeted therapies that are customized to individual characteristics. In addition to traditional methods of preventing relapse, the field of study is currently exploring new and innovative therapeutic approaches. - Neuroprotection refers to enhancing the natural defense mechanisms of the central nervous system to prevent or slow down neurodegenerative processes, which can cause long-term functional decline. -Remyelination: Activating the body's innate ability to regenerate and repair the crucial myelin sheaths, which are necessary for the transmission of nerve impulses and overall neuronal well- being. -Focusing on chronic inflammation: Analyzing the complex network of inflammatory mechanisms that contribute to disease development and harm to neurons. -Methods that modify the immune system's response: Utilizing the inherent healing capabilities of distinct immune cell populations, such as reparative microglia and regulatory T-cells, to coordinate a more sophisticated and regulated immune reaction. Exploring the undisclosed elements that contribute to early risks raises an additional crucial inquiry. The key to precision-targeted therapies lies in identifying individuals who are susceptible to specific disease elements, such as neurodegeneration, heightened inflammation, or the synergistic interplay between them. In order to ensure optimal therapeutic effectiveness and minimize unintended harm, it is imperative that we decode this customized blueprint, allowing us to accurately send the appropriate weapon to the specific combat at the precise moment. The overarching objective of this scientific journey is to achieve complete remission of multiple sclerosis, which is a transformative goal. In order to accomplish this, we must concurrently suppress the intense inflammation and repair the gradual deterioration of the nervous system, targeting the fundamental essence of this complex disorder.
dc.description.courseáltalános orvos
dc.description.courselangangol
dc.description.degreeegységes, osztatlan
dc.format.extent49
dc.identifier.urihttps://hdl.handle.net/2437/367708
dc.language.isoen
dc.rights.accessHozzáférhető a 2022 decemberi felsőoktatási törvénymódosítás értelmében.
dc.subjectMultiple sclerosis
dc.subject.dspaceMedicine::Pharmacology
dc.titleRecent advances in pharmacotherapy of multiple sclerosis
Fájlok
Eredeti köteg (ORIGINAL bundle)
Megjelenítve 1 - 1 (Összesen 1)
Nincs kép
Név:
MD thesis- Shira Turgeman.pdf
Méret:
1.86 MB
Formátum:
Adobe Portable Document Format
Leírás:
Megjelenítés
Engedélyek köteg
Megjelenítve 1 - 1 (Összesen 1)
Nincs kép
Név:
license.txt
Méret:
1.94 KB
Formátum:
Item-specific license agreed upon to submission
Leírás:
Letöltés
Gyűjtemények
Theses (Faculty of Medicine)